Drug General Information
Drug ID	D0Y2GJ
Former ID	DNCL003093
Drug Name	DSP-1053
Indication	Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32]		Phase 1	[524195]
Company	Sunovion Pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	5-hydroxytryptamine 1A receptor	Target Info	Antagonist	[533288]
KEGG Pathway	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Serotonergic synapse
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	5HT1 type receptor mediated signaling pathway
Reactome	Serotonin receptors
	G alpha (i) signalling events
WikiPathways	Serotonin HTR1 Group and FOS Pathway
	SIDS Susceptibility Pathways
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 524195	ClinicalTrials.gov (NCT01774747) A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder. U.S. National Institutes of Health.
Ref 533288	DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats. Pharmacol Res Perspect. 2015 Jun;3(3):e00142.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.